Table 2.

Changes in urinary beta-2-microglobulin concentrations in patients prescribed cisplatin-containing regimens.

# Patients analyzed	Mean cisplatin dose	Cisplatin naïve (yes/no)	# Patients with clinical AKI	Highest mean/median fold change from baseline during the observation period	Timing of peak change	References
35	27–145 mg	No	None	U: ↑ 8.8-fold	Day 0.5	35
8	30–90 mg/m2	Yes	n = 1	U: ↑ up to 10-fold	Day 3	40
20	50 mg/m2 (6 cycles)	Yes	Unknown	U: ↑ 2-fold	Day 0.5	32
57	63.4 mg/m2	Mixed	n = 1	U: ↑ 3.3-fold	Day 3	31
14	70 mg	Unknown	None	U: ↑ 10-fold	Day 4	36
11	<80 mg/m2	Unknown	Unknown	U: No difference between AKI and non-AKI		37
19	80 mg/m2	Yes	None	U: ↑ 6-fold	Day 1 (1–3 hr)	38
14	100 mg/m2 (over 5 days)	No	None	U: ↑ 4.9-fold	Day <5	25
41	100 mg/m2 (over 5 days)(3 cycles)	Unknown	NE	U: Cycle 1: ↑ 474-fold U: Cycle 2: ↑ 551-foldU: Cycle 3: ↑ 63-fold	Cycle 1: Day 6Cycle 2: Day 6Cycle 3: Day 6	27
11	100 mg/m2 (over 5 days)(6 cycles)	Yes	None	U: ↑ 2- to 5-fold	Day 3	33
22	100 mg/m2 (5 cycles)	Yes	None	U: ↓ 1.7-fold	Days 21+	34
12	120 mg/m2	No	NE	U: ↑ 5.7-fold	Day <6	39
30	200 mg/m2 (over 5 days)(3 cycles)	Unknown	Mean 25% ↓ eGFR Day 9	U: Cycle 1: up to 80-fold	Cycle 1: Day 9	26
5	375 mg/m2 (over 5 days)	Yes	None	U: ↑ 13-fold	Day <5	23

AKI: acute kidney injury; eGFR: estimated glomerular filtration rate; NE: not evaluated; S: serum; UK: Unknown; U: urine.

Each publication provides different definitions for the diagnosis of clinical acute kidney injury.